News
Hims & Hers Health, Inc.'s subscriber growth, Novo Nordisk partnership, and FDA pill approval could boost financials. Click ...
StockStory.org on MSN49m
HIMS Q1 Earnings Call: Personalized Care and New Partnerships Drive Upside, Guidance Signals Near-Term TransitionTelehealth company Hims & Hers Health (NYSE:HIMS) announced in Q1 CY2025, with sales up 111% year on year to $586 million.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback